A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs P 500 (Primary)
Indications Adenoid cystic carcinoma; Glioblastoma; Glioma; Lymphoma; Solid tumours; Uveal melanoma
Focus Adverse reactions
Sponsors Prelude Therapeutics

06 Jun 2023 Results (As of January 13, 2023, n=86 )presented at the 59th Annual Meeting of the American Society of Clinical Oncology
03 Apr 2023 Status changed from active, no longer recruiting to completed.
16 Dec 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com